Patents by Inventor Andrew John Walker

Andrew John Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
    Patent number: 7622464
    Abstract: Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents —(CRnaRnb)n—; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 and R4 each independently represent hydrogen or C1-6-alkyl; R7 represents hydrogen or C1-6alkyl; R8 represents hydrogen or C1-6alkyl; and salts and solvates thereof; are CCR3 antagonists and are thus indicated to be useful in therapy.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: November 24, 2009
    Assignee: Glaxo Group Limited
    Inventors: Rachael Ann Ancliff, Caroline Mary Cook, Colin David Eldred, Paul Martin Gore, Lee Andrew Harrison, Martin Alistair Hayes, Simon Teanby Hodgson, Duncan Bruce Judd, Suzanne Elaine Keeling, Xiao Qing Lewell, Gail Mills, Graeme Michael Robertson, Stephen Swanson, Andrew John Walker, Mark Wilkinson
  • Benzenesulphonate salt of a morpholine urea derivative for use as a CCR-3 antagonist in the treatment of inflammatory conditions
    Patent number: 7531651
    Abstract: Compounds of formula (I): wherein A? represents the benzenesulphonate (besylate) anion;. R represents H or C1-6 alkyl; and n is a number from 0.8 to 2.2 are CCR3 antagonists and are therefore indicated to be useful in therapy are described.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: May 12, 2009
    Assignee: Glaxo Group Limited
    Inventors: John Spencer Cook, Robert Philip Landon, Andrew John Walker, Mark Wilkinson